When was Tetraneuron founded?

Tetraneuron was founded in 2012 and raised its 1st funding round 10 years after it was founded.

Where is Tetraneuron located?

Tetraneuron is headquartered in Valencia, Spain.

How many employees does Tetraneuron have?

As of Apr 30, 2026, the latest employee count at Tetraneuron is 20.

Is Tetraneuron a funded company?

Tetraneuron is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 29, 2022.

When was the latest funding round of Tetraneuron?

Tetraneuron's latest funding was a $***** Series A round on Dec 29, 2022, with participation from 0 investor.

Where does Tetraneuron rank among its competitors?

Tetraneuron ranks 290th amongst 493 active competitors, of which 175 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Therapeutics, which secured $13.3M in Oct, 2025.

Who are the top competitors of Tetraneuron?

Tetraneuron's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Among them, Mission Therapeutics secured the most recent funding round in October, 2025.

Tetraneuron - 2026 Company Profile, Team, Funding & Competitors

Tetraneuron is a series A company based in Valencia (Spain), founded in 2012 by Lucia Almonacid Olleros, Jose M Frade and Cristina Payan Rodriguez. It operates as a Developer of gene therapies to treat Alzheimer's disease. Tetraneuron has raised $5M in funding. The company has 493 active competitors, including 175 funded and 90 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Annexon.

Company Details

Developer of gene therapies to treat Alzheimer's disease. It offers a dominant-negative form of E2F4 incapable of being phosphorylated by p38MAPK to prevent the neuronal tetraploidy. It offers pipeline of drug candidates which include TET-101 for Alzheimers, TET-E2F4DH for glaucoma, parkinsons, and aging.

Website: tetraneuron.com
Social
Email ID: *****@tetraneuron.com

Key Metrics

Founded Year

2012

Location

Valencia, Spain

Stage

Series A

Total Funding

$5M in 1 round

Latest Funding Round

Series A, Dec 29, 2022, $*****

Investors

JLABS

Ranked

290^th among 493 active competitors

Employee Count

20 as on Apr 30, 2026

Similar Companies

Denali Therapeutics & 610 more

View Tetraneuron's full profile

Tetraneuron has raised a total funding of $5M over 1 round. Tetraneuron has 1 institutional investor.

Here is the list of recent funding rounds of Tetraneuron:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 29, 2022	2773616	Series A	1597704	3732853	5923247	5814635

Access funding benchmarks and valuations. Sign up today!

View details of Tetraneuron's funding rounds and investors

The founders of Tetraneuron are Lucia Almonacid Olleros, Jose M Frade and Cristina Payan Rodriguez.

Here are the details of Tetraneuron's key team members:

Lucia Almonacid Olleros: Co-Founder of Tetraneuron.
Jose M Frade: Co-Founder of Tetraneuron.
Cristina Payan Rodriguez: Co-Founder of Tetraneuron.

View details of Tetraneuron's Founder profiles and Board Members

Tetraneuron's employee count trend

Tetraneuron has 20 employees as of Apr 26. Here is Tetraneuron's employee count trend over the years:

Uncover Tetraneuron's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tetraneuron include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Here is the list of Top 10 competitors of Tetraneuron, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Baillie Gifford, Bezos Expeditions & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Blackstone, Redmile Group & 16 others	67/100
4th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	Collage Venture Partners, SVB Securities	66/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Orbimed, ATW Partners & 5 others	65/100
7th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$115M	RA Capital Management, SV Health Investors ... & 13 others	64/100
8th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100
9th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	63/100
10th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
290th	Tetraneuron 2012, Valencia (Spain), Series A	Developer of gene therapies to treat Alzheimer's disease	$5M	JLABS	29/100